DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Cervical Clear Cell Adenocarcinoma — screening already-approved drugs against its 10-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCervical Clear Cell Adenocarcinoma maps to a 10-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cervical clear cell adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphatase and tensin homolog (PTEN) — PTEN is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet +drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1D5R · 2.1 Å · ligand L(+)-TARTARIC ACID (TLA). Experimental structure, not a prediction.
What the evidence adds up to
A retrospective analysis of 74 cervical clear cell adenocarcinoma patients treated between 1993 and 2020 reported a median follow-up of 36 months, with 3-year overall survival of 82.4% and progression-free survival of 81.4%. FIGO stage was a prognostic factor for both overall survival and progression-free survival, and lymph node status was a prognostic factor for progression-free survival. No recurrence or death was observed among patients who received fertility-sparing treatment. Among patients who underwent surgery after chemoradiotherapy, five of six had pathological residual disease, including three with pathological risk factors. The authors concluded that fertility-sparing treatment is a safe option for young patients in early stage and that early-stage patients without risk factors may benefit from postoperative surveillance.
Whole-exome sequencing of 24 cervical adenocarcinomas from mainland Chinese patients identified frequently mutated genes in the PI3K-AKT pathway (KRAS, PIK3CA, PTEN), the estrogen signalling pathway (KRAS, PIK3CA, GNAS), and NK cell-mediated antibody-dependent cellular cytotoxicity pathways. Seven patients had HPV infection; mutated genes in HPV-positive tumours were relatively consistent, while mutation profiles in HPV-negative tumours were relatively scattered. The authors suggested potential for individualised treatment based on genomic information, but no treatment outcomes were reported in this sequencing study.
A single case report described a 71-year-old woman with clear cell adenocarcinoma coexisting with squamous cell carcinoma in situ and no history of diethylstilbestrol exposure. The authors stated that clear cell adenocarcinoma, while aggressive, does not necessarily mean an unfavourable prognosis in early clinical stage.
What is still missing: prospective trials testing targeted therapies based on the genomic alterations identified in the sequencing study; any data on response to specific drugs in clear cell adenocarcinoma; validated biomarkers to select patients who will benefit from adjuvant treatment versus surveillance; and a larger, multi-centre cohort to confirm the prognostic factors and fertility-sparing outcomes reported in the retrospective analysis.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Technology in Cancer Research & Treatment · 2023 · 13 citations · open access
Clinical Features and Prognostic Factors of Cervical Clear Cell Adenocarcinoma: A Retrospective Analysis of 74 Cases from a Tertiary Hospital
AbstractThe retrospective study aimed to analyze the clinical characteristics, primary treatment, and prognosis of cervical clear cell adenocarcinoma in a tertiary referral center. The medical data of cervical clear cell adenocarcinoma patients treated in our institution between 1993 and 2020 were reviewed. Their clinical characteristics and information on treatment and follow-up were collected. Seventy-four cases were included. Six early-stage patients successfully preserved their fertility. Forty-five patients underwent a radical hysterectomy. Patients with pathological risk factors all received adjuvant treatment including chemotherapy, radiotherapy, and chemoradiation. Fifteen patients without risk factors underwent surveillance and five patients received adjuvant chemotherapy for poorly differentiated disease. Twenty cases had radiation for primary treatment. Six of them underwent surgery after chemoradiotherapy, and five had pathological residual disease, including three who had pathological risk factors. The median follow-up interval was 36 months, with a 3-year OS and PFS rate of 82.4% and 81.4%, respectively. No recurrence or death was observed in patients with fertility-sparing treatment. FIGO stage was prognostic factors of PFS ( P = .001) and OS( P = .006) and lymph node status was that of PFS ( P = .023). FIGO stage and lymph node status were prognostic factors for survival. Fertility-sparing treatment is a safe option for young patients in early stage. Early-stage patients without risk factors may benefit from postoperative surveillance. Occult tumor after chemoradiotherapy is common, and surgical resection is recommended when operable residual disease is detected.
Translational Cancer Research · 2020 · 3 citations · open access
Whole-exome sequencing in cervical adenocarcinoma in mainland Chinese patients
AbstractBackground: Cervical cancer is the most common gynecological malignancy worldwide. Adenocarcinoma is an important pathological type of cervical cancer. In recent years, the incidence of adenocarcinoma is rising in some countries and the prognosis of it remains poor. A precise description of the mutational landscape in cervical adenocarcinoma may provide insights into a better selection of treatments and improve prognosis. Methods: In this study, we conducted whole-exome sequencing (WES) for cervical adenocarcinomas and matched blood samples from a cohort of 24 mainland Chinese patients. Additionally, the Human-Papilloma virus (HPV) infection statuses of these tumor samples were detected, and the genes that were enriched in both HPV positive and negative samples were also analyzed. Results: The results of WES revealed the gene expression profile of cervical adenocarcinoma of women in mainland China and identified multiple genes/pathways, which are frequently mutated in these tumors, including the PI3K-AKT (KRAS, PIK3CA and PTEN), estrogen signaling (KRAS, PIK3CA and GNAS) and NK cell-mediated antibody-dependent cellular cytotoxicity pathways. Besides, seven patients had HPV infection, and the mutated genes in HPV-positive tumor tissues were relatively consistent, while the mutation profiles of HPV-negative tumor tissues were relatively scattered. Conclusions: Taken together, these findings provide novel insights into the pathogenesis of cervical adenocarcinomas. They suggest the potential for individualized treatment of cervical adenocarcinoma according to genomic information.
Clear cell adenocarcinoma coexisting with squamous cell carcinoma in situ of the uterine cervix-A case report-
AbstractWe report a rare case of clear cell adenocarcinoma (CCAC) of the uterine cervix with squamous cell carcinoma in situ in a 71-year-old woman with no history of intrauterine diethylstilbestrol exposure.Cytological cervical specimens showed sheet-like peripheral rod or spike adenocarcinoma cell clusters and atypical squamous cells with abundant clear focal cytoplasm and prominent nucleoli suggesting CCAC. CCAC, while aggressive, does not necessarily mean an unfavorable prognosis in the early clinical stage. Atypical with ball-or sheet-like cells and clear cytoplasm in cervical smears should thus suggest the possibility of CCAC.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
